Exagen Inc. updated earnings guidance for the full year 2024. For full year 2024 revenue, company is increasing guidance to at least $55 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.945 USD | -1.27% | +1.81% | -1.01% |
14/05 | Cantor Fitzgerald Adjusts Price Target on Exagen to $7 From $5, Maintains Overweight Rating | MT |
13/05 | Exagen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.01% | 34.23M | |
+22.81% | 87.14B | |
-23.63% | 75.59B | |
+1.76% | 26.78B | |
+3.99% | 17.89B | |
-14.13% | 16.44B | |
+2.84% | 15.68B | |
+69.51% | 13.3B | |
+75.92% | 13.06B | |
+3.11% | 12.54B |
- Stock Market
- Equities
- XGN Stock
- News Exagen Inc.
- Exagen Inc. Updates Earnings Guidance for the Full Year 2024